Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry

MGMT-Methylated Alleles Are Distributed Heterogeneously Within Glioma Samples Irrespective ofIDHStatus and Chromosome 10q Deletion

(2016) Laura Fontana et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Epigenetic effects of chromatin remodeling agents on organotypic cultures

(2016) Silvia M Sirchia et al.   Epigenomics

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

(2015) P A Jänne et al.   BRITISH JOURNAL OF CANCER

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique

(2015) Mark Kriegsmann et al.   Diagnostic Pathology

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

(2015) Susan E. Jorge et al.   LUNG CANCER

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid targeted somatic mutation analysis of solid tumors in routine clinical diagnostics

(2015) Gilda Magliacane et al.   Oncotarget

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

(2014) Britta Weber et al.   BMC CANCER

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib

(2014) Boe S. Sorensen et al.   CANCER

Circulating Tumor DNA as a Liquid Biopsy for Cancer

(2014) E. Heitzer et al.   CLINICAL CHEMISTRY

Liquid Biopsies: Genotyping Circulating Tumor DNA

(2014) Luis A. Diaz et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

(2014) Benjamin J. Solomon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Comparison of Methods for EGFR Mutation Testing in Non–Small Cell Lung Cancer

(2013) Elizabeth C. Young et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Emerging protein kinase inhibitors for non-small cell lung cancer

(2013) Stephen V Liu et al.   EXPERT OPINION ON EMERGING DRUGS

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of non-small-cell lung cancer: recent developments

(2013) Martin Reck et al.   LANCET

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)

(2013) Dario de Biase et al.   PLoS One

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

(2012) A. Inoue et al.   ANNALS OF ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers

(2012) Geraldine Perkins et al.   PLoS One

Genomic Pathology: Challenges for Implementation

(2011) Philip T Cagle et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

(2011) Vicki Leigh Keedy et al.   JOURNAL OF CLINICAL ONCOLOGY

Detection of KRAS and BRAF Mutations in Colorectal Carcinoma

(2011) Maria Arcila et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Noninvasive System for Monitoring Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors with Plasma DNA

(2011) Tomomi Nakamura et al.   Journal of Thoracic Oncology